timothy sykes logo
TPST Stock Jumps As Tempest Therapeutics Expands CAR-T Pipeline Thumbnail
G Google News

TPST Stock Jumps As Tempest Therapeutics Expands CAR-T Pipeline

JACK KELLOGG•UPDATED SEP. 16, 2026, 7:47 AM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

Tempest Therapeutics Inc. stocks have been trading up by 38.97 percent following highly positive clinical trial progress news.

Key Takeaways

  • Tempest Therapeutics signed an exclusive option deal with Hebei Senlang for a CD7-targeted lentiviral in vivo CAR-T platform and a portfolio of candidates in cancer and autoimmune disease.
  • The company also obtained rights to Senlang’s in-body CAR-T platform and raised about $2.5M through a warrant-based private placement, with TPST shares spiking 35% after-hours on the news.
  • Management says the Senlang option would complement Tempest Therapeutics’ own CD7-targeted LNP in vivo CAR-T platform, building a broader “immune reset” pipeline.
  • TPST will present its in vivo CAR-T platform and lead asset TPST-4003 at the H.C. Wainwright 28th Annual Global Investment Conference on 2026/09/08, adding a near-term catalyst for traders.

Candlestick Chart

Live Update At 07:47:21 EDT: On Wednesday, September 16, 2026 Tempest Therapeutics Inc. stock [NASDAQ: TPST] is trending up by 38.97%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Tempest Therapeutics (TPST) is still a classic early-stage biotech: promising science, heavy cash burn, and a fragile balance sheet. The latest quarterly numbers through 2026/06/30 show TPST posting a net loss of about $5.24M, or roughly $0.34 per share. That loss flows straight through because Tempest Therapeutics has no reported revenue yet.

Operating cash flow was negative $2.78M for the quarter, and free cash flow matched that. Cash and equivalents sat around $0.78M at period end, with total cash-like assets of about $1.70M. Against that, TPST carries roughly $10.72M in total liabilities and negative equity around -$1.09M. Working capital is deeply negative at about -$2.75M, which tells traders this is a capital-hungry story.

More Breaking News

Key ratios back that up. Tempest Therapeutics’ current ratio of 0.4 and quick ratio of 0.2 show limited near-term liquidity. Returns on assets and equity are sharply negative, as expected when a micro-cap biotech is funding R&D with minimal revenue. In short, TPST remains fundamentally speculative and highly dependent on access to capital and positive trial or deal headlines to support its market value.

Why Traders Are Watching TPST Now

TPST traders just got exactly the kind of catalyst this type of chart lives on: a high-concept pipeline deal tied to an after-hours price surge. On 2026/09/15, Tempest Therapeutics announced an exclusive option agreement with Hebei Senlang Biotechnology. The option covers a CD7-targeted lentiviral in vivo CAR-T platform plus multiple candidates, including a BCMA/GPRC5D dual-targeting CAR-T already in Phase 1 dose escalation for relapsed or refractory multiple myeloma and other hematologic and autoimmune conditions.

For Tempest Therapeutics, that matters. Before this, TPST was primarily an early-stage in vivo CAR-T story with its own CD7-targeted LNP platform. The Senlang deal gives TPST a clinically active asset set that can run alongside its internal work, giving traders more than just one “science bet” to hang a thesis on. Management is positioning this as an “immune reset” franchise, not a single-asset gamble.

At the same time, Tempest Therapeutics raised about $2.5M via a warrant-based private placement tied to the news. On paper, $2.5M is small, but for a roughly $19.75M enterprise value name, it buys some runway and sends a message that TPST can still tap the capital markets. The market reacted fast: TPST shares spiked around 35% after-hours when the deal hit.

From a trading standpoint, that’s the recipe for momentum: a low-priced biotech, a hot buzzword space (in vivo CAR-T), fresh capital, and a sharp price reaction. Add in the upcoming H.C. Wainwright conference appearance on 2026/09/08, where Tempest Therapeutics plans to spotlight both TPST-4003 and its broader in vivo CAR-T platform, and you have a clear calendar catalyst that active TPST traders will track.

Conclusion

For active traders, TPST sits in that sweet but dangerous spot where story, science, and supply of shares all collide. Tempest Therapeutics has layered Senlang’s lentiviral in vivo CAR-T platform onto its own LNP-based CD7 program, building multiple shots on goal in hematologic cancers and autoimmune disease. That strategic move is what triggered the latest 35% after-hours surge, not any sudden change in Tempest Therapeutics’ near-term revenue outlook.

The numbers still tell a tough story. TPST is burning several million dollars per quarter, holding under $1M in cash as of 2026/06/30, and relying on small, dilutive financings like the $2.5M private placement to stay in the game. Negative equity, weak liquidity ratios, and highly negative returns on capital make Tempest Therapeutics a pure high-risk biotech trade, not a steady compounder.

That’s exactly the kind of name momentum traders love to stalk. Thin float, headline-driven spikes, and a clear technical downtrend that can snap back hard when news hits. TPST’s recent daily chart shows a steady slide from the $1.10–$1.20 range down toward the $0.75 area before this deal, a setup that often fuels violent relief rallies.

As Tim Sykes likes to say, “The market doesn’t care about your opinion, only the price action — react to what the chart is telling you and always, always cut losses quickly.” As millionaire penny stock trader and teacher Tim Sykes, says, “Cut losses quickly, let profits ride, and don’t overtrade.”. For TPST, that means treating Tempest Therapeutics as a trading vehicle around news and conferences, not as a long-term promise. Study the chart, know the catalysts, respect the risk, and let the price action guide your plan.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”